Triamcinolone acetonide is a Small Molecule owned by Clearside BioMedical, and is involved in 12 clinical trials, of which 10 were completed, and 2 are ongoing.

Triamcinolone is a glucocorticoid receptor agonist. It binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in synthesis of anti-inflammatory proteins. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.

The revenue for Triamcinolone acetonide is expected to reach a total of $419m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Triamcinolone acetonide NPV Report.

Triamcinolone acetonide is currently owned by Clearside BioMedical. Bausch Health Companies is the other company associated in development or marketing of Triamcinolone acetonide.

Triamcinolone acetonide Overview

Triamcinolone acetonide (Xipere) is a corticosteroid, acts as immunosuppressive and anti-inflammatory agent. It is formulated as suspension for suprachoroidal route of administration. Xipere is indicated for the treatment of macular edema associated with uveitis.

Triamcinolone acetonide (CLS1001) is under development for the treatment of non-infectious intermediate, posterior and pan-uveitis, diabetic macular edema, Uveitic Macular Edema and macular edema associated with non-infectious uveitis. The drug is administered as a suprachoroidal injectable suspension and acts by targeting the glucocorticoid receptors. It was also under development for sympathetic ophthalmia, temporal arteritis, ocular inflammatory conditions, branch retinal vein occlusion and central retinal vein occlusion.

Clearside BioMedical Overview

Clearside BioMedical (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products comprise of CLS-AX, XIPERE and SCS Microinjector. Clearside’s proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight threatening disease often occurs. The company also offers services such as business development, license agreements and contract manufacturing services. Clearside has partners with various pharmaceutical companies for the commercialization and development of its products across the US, Canada, China, Hong Kong, Macau, Taiwan and South Korea, among others. It markets its products across the US. Clearside is headquartered in Alpharetta, Georgia, the US.

The company reported revenues of (US Dollars) US$29.6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$7.9 million in FY2020. The operating profit of the company was US$0.4 million in FY2021, compared to an operating loss of US$17.9 million in FY2020. The net profit of the company was US$0.4 million in FY2021, compared to a net loss of US$18.2 million in FY2020. The company reported revenues of US$0.3 million for the third quarter ended September 2022, a decrease of 30.7% over the previous quarter.

Quick View – Triamcinolone acetonide

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Triamcinolone acetonide
Administration Pathway
  • Intraocular
Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Ophthalmology
Key Companies
  • Sponsor Company: Clearside BioMedical
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.